EU-domstolen · Dom
C-611/16 PXellia Pharmaceuticals ApS and Alpharma, LLC, anciennement Zoetis Products LLC v European Commission
- Avgjort
- 2021-03-25
- ECLI
- ECLI:EU:C:2021:245
- CELEX
- 62016CJ0611
- Rettskraft
- Endelig, avgjørelsen kan ikke ankes
Domstolens egne nøkkelord
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine – Rights of the defence – Reasonable time – Loss of documents due to the passage of time – General duty of care – Regulation (EC) No 1/2003 – Second subparagraph of Article 23(2) – Maximum amount of the fine – Taking into account the business year preceding that in which the European Commission’s decision was adopted – Last full year of normal economic activity.
Tolker
Lest hos EU:s publikationsbyrå, Cellar (EUR-Lex och CURIA) den 2026-08-22.
Raden gjengir det kilden skriver. Den er ikke et referat, ikke en konklusjon om en enkelt sak og ikke juridisk rådgivning.
Kontrollerbare tillitssignaler
- Seks faste blokker, én kilde per linje
- Ingen setning skrevet av en språkmodell
- Motorversjon og lesedato på hvert svar
- Ingen kundedata, ingen dokumenter, ingen rådgivning
- Modellkort og revisjon publisert etter AI-forordningen